



## Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will present at the 40<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 1:30 p.m. ET.

The conference will be held virtually. A live webcast of the call can be accessed under Events & Presentations in the Investors section of the Vir website at [www.vir.bio](http://www.vir.bio) and will be archived there for 30 days.

### About Vir Biotechnology

Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit [www.vir.bio](http://www.vir.bio).

### Contacts:

#### Investors

Heather Rowe Armstrong  
VP, Investor Relations  
[harmstrong@vir.bio](mailto:harmstrong@vir.bio)  
+1-415-915-4228

#### Media

Cara Miller  
VP, Corporate Communications  
[cmiller@vir.bio](mailto:cmiller@vir.bio)  
+1-415-941-6746



Source: Vir Biotechnology, Inc.